C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Research analysts at Brookline Capital Markets dropped their FY2029 earnings per share estimates for C4 Therapeutics in a research report issued on Tuesday, August 11th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of $5.90 per share for the year, down from their previous estimate of $6.14. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($0.87) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ FY2030 earnings at $22.46 EPS.
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, C4 Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.
C4 Therapeutics Price Performance
CCCC opened at $3.87 on Wednesday. C4 Therapeutics has a fifty-two week low of $1.69 and a fifty-two week high of $5.17. The firm has a market capitalization of $427.91 million, a price-to-earnings ratio of -3.25 and a beta of 2.91. The company’s 50 day moving average price is $3.91 and its two-hundred day moving average price is $3.16.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $6.64 million during the quarter, compared to the consensus estimate of $4.00 million. C4 Therapeutics had a negative return on equity of 50.68% and a negative net margin of 297.76%.
Institutional Investors Weigh In On C4 Therapeutics
Institutional investors have recently modified their holdings of the company. SummitTX Capital L.P. acquired a new stake in shares of C4 Therapeutics during the first quarter worth $28,000. CTC Alternative Strategies Ltd. acquired a new position in C4 Therapeutics in the first quarter valued at $28,000. Zacks Investment Management acquired a new position in C4 Therapeutics in the third quarter valued at $29,000. Delta Investment Management LLC bought a new stake in C4 Therapeutics during the fourth quarter valued at $38,000. Finally, Virtu Financial LLC bought a new stake in C4 Therapeutics during the fourth quarter valued at $39,000. 78.81% of the stock is owned by institutional investors.
C4 Therapeutics Company Profile
C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.
The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.
Featured Stories
- Five stocks we like better than C4 Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
